The 'Picks and Shovels' Play
An analysis of bioprocessing firm Repligen offers a strategic parallel for manufacturing. The company's success with a 'razor and blade' model—selling essential equipment and proprietary consumables—creates high switching costs and customer lock-in, a potential model for specialized tooling in any high-stakes manufacturing environment.
Repligen's model is anchored in four key franchises: Filtration, Chromatography, Proteins, and Process Analytics, which are essential for manufacturing biologic drugs. The company's revenue for full-year 2025 reached $738 million, reflecting 16% organic growth, with filtration products accounting for roughly 58% of that total. The "razor and blade" strategy is common in the tech world; video game console makers often sell hardware at a low margin to profit from high-margin proprietary games. Similarly, the value of an inkjet printer is dwarfed by the long-term, recurring revenue from its proprietary ink cartridges. This model is designed to create a reliable, long-term income stream by locking a consumer onto a specific platform. This customer lock-in is achieved through high switching costs, which can be procedural and financial. For a manufacturer, switching a critical component supplier risks costly factory downtime, loss of data, and the need to retrain the workforce on new systems. These barriers create a powerful economic moat, making customers less sensitive to competitors' pricing. Repligen aggressively expands its portfolio of "blades" through strategic acquisitions. The company has completed 11 acquisitions to date, recently purchasing the bioprocessing analytics portfolio from 908 Devices and acquiring Tantti Laboratory to strengthen its offerings for new drug modalities like gene therapies and mRNA vaccines. This M&A activity contributed about one point to reported revenue growth in 2025. In semiconductor fabrication, this model translates to highly specialized equipment and the proprietary materials or software required for its operation. As processes become more complex and yields are paramount, the cost of re-validating a production line with a new supplier's equipment can be prohibitive, effectively locking in the original vendor. This dynamic is critical in the context of Apple's expanding domestic manufacturing footprint and its more than $500 billion commitment to U.S. investment. The build-out of a U.S. silicon supply chain with partners like TSMC in Arizona and Corning in Kentucky creates significant opportunities for suppliers who can embed their proprietary technology directly into these new, high-stakes production lines.
